Technology
Health
Pharmaceutical

Moleculin Biotech

$1.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-3.25%) As of 3:40 PM EDT today
-$0.04 (-3.25%) Today

Why Robinhood?

You can buy or sell MBRX and other stocks, options, ETFs, and crypto commission-free!

About MBRX

Moleculin Biotech, Inc. Common Stock, also called Moleculin Biotech, is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Read More Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Employees
9
Headquarters
Houston, Texas
Founded
2015
Market Cap
42.32M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
447.25K
High Today
$1.30
Low Today
$1.17
Open Price
$1.30
Volume
1.09M
52 Week High
$3.15
52 Week Low
$0.7772

Collections

Technology
Health
Pharmaceutical
Medical
2016 IPO
US
North America

MBRX News

Benzinga6h

Moleculin Investors Rewarded As Annamycin Trial Advances To Next Cohort

51
BenzingaJul 10

Moleculin Rallies On Patent Applications That Could Give Cancer Drug 20 Years of Protection

838

MBRX Earnings

-$0.20
-$0.16
-$0.12
-$0.08
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 13, After Hours

More MBRX News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.